High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.
about
High throughput protein nanocrystal fractionation in a microfluidic sorterAlternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MSOlomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)In vitro and in vivo metabolism and inhibitory activities of vasicine, a potent acetylcholinesterase and butyrylcholinesterase inhibitorDose-Independent ADME Properties and Tentative Identification of Metabolites of α-Mangostin from Garcinia mangostana in Mice by Automated Microsampling and UPLC-MS/MS MethodsMetabolic profiling of Shu-Yu capsule in rat serum based on metabolic fingerprinting analysis using HPLC-ESI-MSnIdentification of metabolites of gardenin A in rats by combination of high-performance liquid chromatography with linear ion trap-Orbitrap mass spectrometer based on multiple data processing techniques.Identification of major metabolites in rat urine and plasma of N(6) -(4-hydroxybenzyl) adenine riboside by LC/MS/MS.Recent application of analytical methods to phase I and phase II drugs development: a review.Tandem mass spectrometry study of p38α kinase inhibitors and related substances.Distribution study of atorvastatin and its metabolites in rat tissues using combined information from UHPLC/MS and MALDI-Orbitrap-MS imaging.Analysis of the metabolic profile of parishin by ultra-performance liquid chromatography/quadrupole-time of flight mass spectrometry.Identification of transformation products from β-blocking agents formed in wetland microcosms using LC-Q-ToF.Preparation and structural determination of four metabolites of senkyunolide I in rats using ultra performance liquid chromatography/quadrupole-time-of-flight tandem mass and nuclear magnetic resonance spectraProfiling and identification of chlorogenic acid metabolites in rats by ultra-high-performance liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometer.Regiospecificity of human UDP-glucuronosyltransferase isoforms in chalcone and flavanone glucuronidation determined by metal complexation and tandem mass spectrometry.A computational drug metabolite detection using the stable isotopic mass-shift filtering with high resolution mass spectrometry in pioglitazone and flurbiprofenA comprehensive workflow of mass spectrometry-based untargeted metabolomics in cancer metabolic biomarker discovery using human plasma and urineDatabase searching for structural identification of metabolites in complex biofluids for mass spectrometry-based metabonomics.Advances in bioanalytical LC-MS using the Orbitrap™ mass analyzer.Restricted-access media supports for direct high-throughput analysis of biological fluid samples: review of recent applications.Novel MS solutions inspired by MIST.Glutathione, glutathione S-transferase, and glutathione conjugates, complementary markers of oxidative stress in aquatic biota.An introduction to hybrid ion trap/time-of-flight mass spectrometry coupled with liquid chromatography applied to drug metabolism studies.Metabolite structure analysis by high-resolution MS: supporting drug-development studies.Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides.Mass spectrometry and NMR spectroscopy: modern high-end detectors for high resolution separation techniques--state of the art in natural product HPLC-MS, HPLC-NMR, and CE-MS hyphenations.Recent advances in simultaneous analysis of bisphenol A and its conjugates in human matrices: Exposure biomarker perspectives.Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes.A powerful couple in the future of clinical biochemistry: in situ analysis of dried blood spots by ambient mass spectrometry.One drop chemical derivatization--DESI-MS analysis for metabolite structure identification.Stable isotope labeling strategy for curcumin metabolite study in human liver microsomes by liquid chromatography-tandem mass spectrometry.Analysis of chloroquine and metabolites directly from whole-body animal tissue sections by liquid extraction surface analysis (LESA) and tandem mass spectrometry.Differences in metabolism of the marine biotoxin okadaic acid by human and rat cytochrome P450 monooxygenases.Differential oxidative metabolism and 5-ketoclomazone accumulation are involved in Echinochloa phyllopogon resistance to clomazone.Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT.Identification of the metabolites of ecabet bismuth in rat bile by liquid chromatography-electrospray ionization-tandem mass spectrometry.Widespread occurrence and seasonal variation of pharmaceuticals in surface waters and municipal wastewater treatment plants in central Finland.Using electron induced dissociation (EID) on an LC time-scale to characterize a mixture of analogous small organic molecules.Strategies for ascertaining the interference of phase II metabolites co-eluting with parent compounds using LC-MS/MS.
P2860
Q27301897-51EF440B-8E87-4844-8509-4CCD796C7F98Q28083408-ABCECA00-DB49-4146-99E9-A2C9A1C64EF4Q28534229-D216688D-1ACF-440C-80DA-761433F7F9EBQ28545861-293C4598-179B-4763-9161-196122BF3E30Q28546533-D1B6A2EA-13EE-4442-8416-B1883A9CA100Q28834503-0B56B4BC-FA61-4B63-822A-3275F2A63615Q30837381-169B587F-FD15-4776-BE15-4CA4A6C40AD7Q33756541-B0B94DE1-2BAB-4C14-8009-819B4B6DB0A4Q33997398-32E5177F-DE52-4163-B942-8F433BE17854Q34748950-F0D400DE-4F34-4FC6-B70D-A12DC673E648Q35171225-764F446A-1E23-440F-9C7E-6078DE2AECCFQ35641562-2A545A09-692C-4F82-9DF6-F20F21EF9F4AQ35950022-E3AF0E34-302E-401E-89FD-338FC0FEB386Q36213697-F64327B1-A2E0-49FB-87C9-571EF61BD751Q36408789-169A817F-4910-4E73-9BBA-E9F149256BA8Q37010122-AC3159D5-8DB4-4EB2-8906-29905AA4462AQ37291167-7B3A4500-1333-4FE5-8D22-AFD2F9215CEFQ37512825-69131A7B-18CC-44CC-8127-8D64E05A5F57Q37810165-599F73F9-F781-4B61-8F0B-B79A68E8E581Q37810178-1E0DE420-226C-4BE7-B85B-93C330DF5EE6Q37810189-F0DB9185-3AB4-4350-A22D-7E05ECA6E6C9Q37810230-F964B27D-94E9-4927-9D96-A93B75ED1C3CQ38005339-6579DED3-E5FF-46E9-86FB-FFE4BA050F75Q38071001-B123012A-6062-4E50-8691-8304F7BE4C8EQ38081958-419A1554-1861-4CFE-8533-382EBFBBD72EQ38104574-49F2FECD-C05B-41E3-B2C3-5B0C9C8721A8Q38112324-8260EF72-AC95-40DB-B267-20EBAF4B654FQ38944199-8D343E73-D981-452C-9AB8-83F63A6DC9C6Q39791357-5A7D9AD1-CDE4-4BC5-B39B-2B758EB3EA3CQ39816327-89EEFBF2-00D1-476C-A105-7CF75A92BC8DQ40562448-70807BBA-6D22-4BBA-BE1F-4506E368386DQ41577147-9101E5EE-7EE8-40DA-9B03-2EB757032FE4Q41927799-A02273E6-531B-4ED7-AB29-EE4B1454E178Q42700600-77A64BC3-16BE-4550-ACEE-D7796FD19BCCQ43140617-76926EC9-4930-435A-9A31-749696F9BECBQ43176490-58BA31AB-84D1-4204-95D7-97099482BB70Q43297108-3F369BCF-9F4B-4701-B3DB-935525881A58Q43343620-459B5FA5-9268-4FC1-B7F9-0C87D902F17EQ44923005-22BF02AD-32D5-49F2-BB13-A0032E87CBB8Q44996296-7B9EA5D1-D982-44F6-8C51-83A7FA0B0635
P2860
High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
High-performance liquid chroma ...... and phase II drug metabolites.
@ast
High-performance liquid chroma ...... and phase II drug metabolites.
@en
type
label
High-performance liquid chroma ...... and phase II drug metabolites.
@ast
High-performance liquid chroma ...... and phase II drug metabolites.
@en
prefLabel
High-performance liquid chroma ...... and phase II drug metabolites.
@ast
High-performance liquid chroma ...... and phase II drug metabolites.
@en
P2093
P2860
P1476
High-performance liquid chroma ...... and phase II drug metabolites.
@en
P2093
P2860
P2888
P356
10.1007/S00216-008-1962-7
P407
P577
2008-03-15T00:00:00Z
2008-05-01T00:00:00Z